Skip to main content
Erschienen in: International Urology and Nephrology 4/2009

01.12.2009 | Nephrology - Original Paper

Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic populations

verfasst von: Josée Bouchard, Denis Ouimet, Michel Vallée, Jean-Philippe Lafrance, Martine Leblanc, Lyne Sénécal, Alain Bonnardeaux, Jean-Pierre Mathieu, Vincent Pichette

Erschienen in: International Urology and Nephrology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Aim

Calcidiol insufficiency is highly prevalent in chronic kidney disease (CKD) and osteoporotic patients. We assessed and compared calcidiol levels in these two groups from the same geographical area to differentiate environmental factors from characteristics related to CKD.

Methods

We measured calcidiol levels in 160 predialysis (group 1) and 53 osteoporotic (group 2) patients from a single center. Calcidiol insufficiency was defined as a level between 37.5 and 75 nmol/l and calcidiol deficiency was defined as a level below 37.5 nmol/l.

Results

In group 1, mean glomerular filtration rate (GFR), calcidiol, and parathyroid hormone (PTH) levels were 18.3 ± 4.7 ml/min, 38.7 ± 15.1 nmol/l, and 21.9 ± 19.1 pmol/l. Calcidiol insufficiency and deficiency were present in 98.7% of patients. There was an inverse correlation between calcidiol and PTH levels (r = −0.25; P = 0.001). In group 2, mean GFR, calcidiol levels, and PTH levels were 68.6 ± 17.6 ml/min, 73.8 ± 27.1 nmol/l, and 4.23 ± 1.83 pmol/l, respectively. Calcidiol insufficiency and deficiency were present in 50.9% of patients. There was an inverse correlation between calcidiol and PTH levels (r =−0.44; P = 0.02).

Conclusion

In our predialysis population, calcidiol insufficiency and deficiency are present in almost every patient, being more common than previously reported. It is also more frequent than in a similar osteoporotic population, suggesting a cause unrelated to environmental factors. Interestingly, there is a significant inverse correlation between calcidiol and parathyroid levels in both populations. Further studies are needed to enable understanding of the mechanisms underlying calcidiol insufficiency.
Literatur
1.
Zurück zum Zitat Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ (2004) Vitamin d insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24:503–510CrossRefPubMed Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ (2004) Vitamin d insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24:503–510CrossRefPubMed
2.
Zurück zum Zitat LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM (2005) Prevalence of calcidiol deficiency in ckd: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45:1026–1033CrossRefPubMed LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM (2005) Prevalence of calcidiol deficiency in ckd: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45:1026–1033CrossRefPubMed
3.
Zurück zum Zitat Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A (1999) Is low plasma 25-(oh) vitamin d a major risk factor for hyperparathyroidism and looser’s zones independent of calcitriol? Kidney Int 55:2169–2177CrossRefPubMed Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A (1999) Is low plasma 25-(oh) vitamin d a major risk factor for hyperparathyroidism and looser’s zones independent of calcitriol? Kidney Int 55:2169–2177CrossRefPubMed
4.
Zurück zum Zitat National Kidney Foundation (2003) K/doqi clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S201 National Kidney Foundation (2003) K/doqi clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S201
5.
Zurück zum Zitat Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin d, pth, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38CrossRefPubMed Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin d, pth, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38CrossRefPubMed
6.
Zurück zum Zitat LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J (1999) Occult vitamin d deficiency in postmenopausal us women with acute hip fracture. JAMA 281:1505–1511CrossRefPubMed LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J (1999) Occult vitamin d deficiency in postmenopausal us women with acute hip fracture. JAMA 281:1505–1511CrossRefPubMed
7.
Zurück zum Zitat Sahota O, Mundey MK, San P, Godber IM, Lawson N, Hosking DJ (2004) The relationship between vitamin d, parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35:312–319CrossRefPubMed Sahota O, Mundey MK, San P, Godber IM, Lawson N, Hosking DJ (2004) The relationship between vitamin d, parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35:312–319CrossRefPubMed
8.
Zurück zum Zitat Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T (2001) A global study of vitamin d status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86:1212–1221CrossRefPubMed Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T (2001) A global study of vitamin d status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86:1212–1221CrossRefPubMed
9.
Zurück zum Zitat Binkley N, Novotny R, Krueger D, Kawahara T, Daida YG, Lensmeyer G, Hollis BW, Drezner MK (2007) Low vitamin d status despite abundant sun exposure. J Clin Endocrinol Metab 92:2130–2135CrossRefPubMed Binkley N, Novotny R, Krueger D, Kawahara T, Daida YG, Lensmeyer G, Hollis BW, Drezner MK (2007) Low vitamin d status despite abundant sun exposure. J Clin Endocrinol Metab 92:2130–2135CrossRefPubMed
10.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470PubMed
11.
Zurück zum Zitat Sorva A (1992) “Correction” of serum calcium values for albumin biased in geriatric patients. Arch Gerontol Geriatr 15:59–69CrossRefPubMed Sorva A (1992) “Correction” of serum calcium values for albumin biased in geriatric patients. Arch Gerontol Geriatr 15:59–69CrossRefPubMed
12.
Zurück zum Zitat Taskapan H, Wei M, Oreopoulos DG (2006) 25(oh) Vitamin d3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 38:323–329CrossRefPubMed Taskapan H, Wei M, Oreopoulos DG (2006) 25(oh) Vitamin d3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 38:323–329CrossRefPubMed
13.
Zurück zum Zitat Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H (1999) Serum levels of 1,25-dihydroxyvitamin d, 24,25-dihydroxyvitamin d, and 25-hydroxyvitamin d in nondialyzed patients with chronic renal failure. Kidney Int 55:1019–1027 Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H (1999) Serum levels of 1,25-dihydroxyvitamin d, 24,25-dihydroxyvitamin d, and 25-hydroxyvitamin d in nondialyzed patients with chronic renal failure. Kidney Int 55:1019–1027
14.
Zurück zum Zitat Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH (1987) Metabolic inactivation of vitamin d is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 73:659–664 Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH (1987) Metabolic inactivation of vitamin d is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 73:659–664
15.
Zurück zum Zitat Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ (2007) Changes in serum 25-hydroxyvitamin d and plasma intact pth levels following treatment with ergocalciferol in patients with ckd. Am J Kidney Dis 50:59–68CrossRefPubMed Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ (2007) Changes in serum 25-hydroxyvitamin d and plasma intact pth levels following treatment with ergocalciferol in patients with ckd. Am J Kidney Dis 50:59–68CrossRefPubMed
16.
Zurück zum Zitat DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH (2006) Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin d in chronic kidney disease. Nephrology (Carlton) 11:555–559CrossRef DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH (2006) Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin d in chronic kidney disease. Nephrology (Carlton) 11:555–559CrossRef
17.
Zurück zum Zitat Kovesdy CP, Kalantar-Zadeh K (2008) Bone and mineral disorders in pre-dialysis ckd. Int Urol Nephrol 40:427–440CrossRefPubMed Kovesdy CP, Kalantar-Zadeh K (2008) Bone and mineral disorders in pre-dialysis ckd. Int Urol Nephrol 40:427–440CrossRefPubMed
18.
Zurück zum Zitat Peters BS, Moyses RM, Jorgetti V, Martini LA (2007) Effects of parathyroidectomy on bone remodeling markers and vitamin d status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol 39:1251–1256CrossRefPubMed Peters BS, Moyses RM, Jorgetti V, Martini LA (2007) Effects of parathyroidectomy on bone remodeling markers and vitamin d status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol 39:1251–1256CrossRefPubMed
19.
Zurück zum Zitat Rickers H, Christiansen C, Christensen P, Christensen M, Rodbro P (1985) Serum concentrations of vitamin d metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24, 25-dihydroxyvitamin d. Nephron 39:267–271CrossRefPubMed Rickers H, Christiansen C, Christensen P, Christensen M, Rodbro P (1985) Serum concentrations of vitamin d metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24, 25-dihydroxyvitamin d. Nephron 39:267–271CrossRefPubMed
20.
Zurück zum Zitat Reichel H, Deibert B, Schmidt-Gayk H, Ritz E (1991) Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6:162–169PubMed Reichel H, Deibert B, Schmidt-Gayk H, Ritz E (1991) Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6:162–169PubMed
21.
Zurück zum Zitat Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E (1988) Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34:368–375CrossRefPubMed Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E (1988) Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34:368–375CrossRefPubMed
22.
Zurück zum Zitat Houghton LA, Vieth R (2006) The case against ergocalciferol (vitamin d2) as a vitamin supplement. Am J Clin Nutr 84:694–697PubMed Houghton LA, Vieth R (2006) The case against ergocalciferol (vitamin d2) as a vitamin supplement. Am J Clin Nutr 84:694–697PubMed
23.
Zurück zum Zitat Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, DeLuca HF, Drezner MK (2004) Assay variation confounds the diagnosis of hypovitaminosis d: a call for standardization. J Clin Endocrinol Metab 89:3152–3157CrossRefPubMed Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, DeLuca HF, Drezner MK (2004) Assay variation confounds the diagnosis of hypovitaminosis d: a call for standardization. J Clin Endocrinol Metab 89:3152–3157CrossRefPubMed
Metadaten
Titel
Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic populations
verfasst von
Josée Bouchard
Denis Ouimet
Michel Vallée
Jean-Philippe Lafrance
Martine Leblanc
Lyne Sénécal
Alain Bonnardeaux
Jean-Pierre Mathieu
Vincent Pichette
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 4/2009
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-008-9509-6

Weitere Artikel der Ausgabe 4/2009

International Urology and Nephrology 4/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.